{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-066458","form_type":"8-K","ticker":"PSNL","cik":"0001527753","company_name":"Personalis, Inc.","filed_at":"2023-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.377776+00:00","generated_at":"2026-06-07T21:00:28.945066+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Personalis enters commercialization agreement with Tempus Labs for NeXT Personal Dx assay","bullets":["Tempus will pay Personalis up to $12,000,000 in Market Development Fee, including a $3M activation fee.","Personalis issued two warrants to Tempus to purchase up to 4,609,400 shares each at $1.50 and $2.50 per share.","Tempus will market Personalis' NeXT Personal Dx assay for breast cancer, lung cancer, and immuno-oncology monitoring.","The agreement has a five-year term with exclusivity until December 31, 2027, and includes milestones for up to $12M in fees."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-066458","json":"https://secwatch.observer/filing/0000950170-23-066458.json","markdown":"https://secwatch.observer/filing/0000950170-23-066458.md","text":"https://secwatch.observer/filing/0000950170-23-066458.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527753/000095017023066458/0000950170-23-066458-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527753/000095017023066458/psnl-20231125.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T21:00:28.945066+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d204aa54a6caeeed997ba02bc5d7356e50a0795e","claim":"Personalis, Inc. entered into Commercialization and Reference Laboratory Agreement with Tempus Labs, Inc. valued at up to $12,000,000 in the aggregate (effective 2023-11-25).","evidence_excerpt":"On November 25, 2023 (the “Effective Date”), Personalis, Inc. (the “Company”) and Tempus Labs, Inc. (“Tempus”) entered into a Commercialization and Reference Laboratory Agreement (the “Tempus Agreement”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527753/000095017023066458/0000950170-23-066458-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Tempus Labs, Inc."},{"label":"Value","value":"up to $12,000,000 in the aggregate"},{"label":"Effective","value":"2023-11-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}